Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth.
Title | Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. |
Publication Type | Journal Article |
Year of Publication | 2015 |
Authors | Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Sadaoui NC, Stone RL, Matsuo K, Dalton HJ, Previs RA, Jennings NB, Dorniak P, Hansen JM, Arevalo JMG, Cole SW, Lutgendorf SK, Sood AK, Lopez-Berestein G |
Journal | Oncotarget |
Volume | 6 |
Issue | 6 |
Pagination | 4266-73 |
Date Published | 2015 Feb 28 |
ISSN | 1949-2553 |
Keywords | Animals, Carcinoma, Chemokine CCL2, Chemotaxis, Leukocyte, Enzyme-Linked Immunosorbent Assay, Epinephrine, Female, Humans, Kaplan-Meier Estimate, Macrophages, Mice, Mice, Nude, Norepinephrine, Ovarian Neoplasms, Real-Time Polymerase Chain Reaction, Stress, Psychological |
Abstract | Increased adrenergic signaling facilitates tumor progression, but the underlying mechanisms remain poorly understood. We examined factors responsible for stress-mediated effects on monocyte/macrophage recruitment into the tumor microenvironment, and the resultant effects on tumor growth. In vitro, MCP1 was significantly increased after catecholamine exposure, which was mediated by cAMP and PKA. Tumor samples from mice subjected to daily restraint stress had elevated MCP1 gene and protein levels, increased CD14+ cells, and increased infiltration of CD68+ cells. hMCP1 siRNA-DOPC nanoparticles significantly abrogated daily restraint stress-induced tumor growth and inhibited infiltration of CD68+ and F4/80+ cells. In ovarian cancer patients, elevated peripheral blood monocytes and tumoral macrophages were associated with worse overall survival. Collectively, we demonstrate that increased adrenergic signaling is associated with macrophage infiltration and mediated by tumor cell-derived MCP1 production. |
DOI | 10.18632/oncotarget.2887 |
Alternate Journal | Oncotarget |
PubMed ID | 25738355 |
PubMed Central ID | PMC4414188 |
Grant List | 5RC2GM09259 / GM / NIGMS NIH HHS / United States 5U54CA151668 / CA / NCI NIH HHS / United States CA016672 / CA / NCI NIH HHS / United States CA101642 / CA / NCI NIH HHS / United States CA104825 / CA / NCI NIH HHS / United States CA109298 / CA / NCI NIH HHS / United States CA140933 / CA / NCI NIH HHS / United States P30 CA016672 / CA / NCI NIH HHS / United States P50 CA083639 / CA / NCI NIH HHS / United States P50 CA093459 / CA / NCI NIH HHS / United States P50CA083639 / CA / NCI NIH HHS / United States P50CA098258 / CA / NCI NIH HHS / United States R01 CA109298 / CA / NCI NIH HHS / United States R01 CA140933 / CA / NCI NIH HHS / United States U54 CA 096300-08 / CA / NCI NIH HHS / United States U54 CA096297 / CA / NCI NIH HHS / United States U54CA151668 / CA / NCI NIH HHS / United States U54CA96297 / CA / NCI NIH HHS / United States U54CA96300 / CA / NCI NIH HHS / United States |